Víctor Albarrán Fernández, Medical Oncologist and Researcher of Cell Therapy for Solid Tumors at Hospital Clínic de Barcelona, shared a post on LinkedIn:
“An incredible review on CAR-T therapy in solid tumors by the group of Dr. Marcela Maus, highly recommended for anyone working on the field!
Some Highlights:
- Clinical momentum is finally here: promising data from CARs targeting IL-13R/EGFR in glioblastoma, CLDN18.2 in GI tumors, GD2 in neuroblastoma/some gliomas, and GPC3 in HCC, among others.
- Multi-antigen targeting to prevent escape (dealing with heterogeneous and pre-treated tumors!).
- Local delivery + repeated administration = better efficacy and safety.
- Armored CAR-T cells to reprogram a hostile TME, with first clinical data emerging (e.g., IL-15-armored GPC3 CAR-Ts).
- Promising combinations with T cell engagers, mRNA vaccines, and other synergistic drugs.
- Rapid innovation via genetic engineering (e.g., KO of immunosuppressive genes) and synthetic biology (tunable switches, receptors, logic circuits, etc).
- Moving toward more sophisticated humanized/syngeneic models for reproducible in vivo validation.
Exciting times ahead for smarter, more powerful cell therapy.”
More posts featuring Víctor Albarrán Fernández.